George Clinical is proud to have been involved in developing the recently announced recommendations by the Clinical Trial Transformation Initiative (CTTI): The Recommendations for Engaging Patients and Sites in Mobile Clinical Trials. The recommendations, to which George Clinical contributed as a member on the expert committee, aim to help research organizations, sponsors, and other stakeholders […]
Read More
George Clinical, a leading full-service CRO in the US and Asia-Pacific region, is pleased to announce that Matthew Reabold, Sr. has been promoted to the Head of Business Development, USA. George Clinical, headquartered in Sydney, Australia, operates in fifteen countries around the world and has major operational hubs in the USA, East Asia, China, and India. Matthew, who is USA based, will […]
Read More
Increasingly, regulatory authorities are placing significant focus on clinical trial processes that ensure consistent, standardized, objective and unbiased reporting of safety and efficacy results; given that the definitions for many endpoint events include subjective components, and investigator-to-investigator subjective assessments may differ. Moreover, an increasing number of trials are now conducted in multiple geographies, and clinical […]
Read More
In the world of healthcare, time is always of the essence. Researchers are continuously looking for new solutions to help improve patients’ well-being and ultimately save lives. The discovery process of new treatments takes an enormous amount of time and resources in order to generate good evidence to prove that they are safe and that […]
Read More
A key step in developing a new drug is the transition from the laboratory to the human subject in a Phase I clinical trial, where the new compound is given to humans for the first time. A Phase I trial is the gateway between scientific research and clinical medicine. Generally, in-human Phase I studies are […]
Read More
For over 30 years, India has been conducting global clinical trials. With over 500 sites and over a billion people, India was a key destination for clinical trials for its vast treatment naïve clinical population. However, the environment has fluctuated throughout recent years, as The Central Drugs Standard Control Organization (CDSCO), India’s regulatory agency for […]
Read More
Health systems in low and middle income countries continue to face considerable challenges in providing high-quality, affordable and universally accessible care – this is primarily evident in rural areas. As of 2014, approximately 876.1 million people live in rural areas within India with poor access to primary healthcare. This amounts to more than two-thirds of […]
Read More
New research from the International Childhood Cancer Cohort Consortium (I4C) confirms that childhood cancer is linked to birthweight. The incidence of childhood cancer appears to be slowly rising, at a rate of approximately 1% per year in developed countries. Link between birthweight and cancer Risk rose by 26 percent for every kilogram increase in birthweight for […]
Read More
China’s meteoric growth over the past twenty years (or so) has seen it go from strength to strength, particularly in the clinical trials sector. As the clinical trial market of the world’s most populous nation (and second largest economy) continues to mature, so does their regulatory requirements. These regulatory adjustments pose a risk to sponsors […]
Read More
Generally, the unit of randomization in a randomized clinical trial (RCT) is the individual participant (the patient). Occasionally, the unit of randomization can be a cluster, such as hospitals, schools, villages, etc. When randomizing large groups, the concept of cluster randomized trials (CRTs) has become increasingly common. Patient clusters are allocated to the intervention arms […]
Read More
